GPC/SPPI:
GPC is up about 7% on the German exchanges.
The way I value royalty revenue is about 1.5x - 2x higher multiple of ordinary revenue. Then one needs to consider GPC vs. Spectrum pipeline. I am only aware of GPC's antibody program (I believe for NHL) which is still early stage. SPPI has two other key drugs in EOquin and Ozarelix. They also have a number of other smaller/earlier stage products. I think SPPI-1620 may turn out to be an interesting drug candidate. Granted it is still preclinical but I believe Spectrum will enter Phase 1 later this year with it. It is an adjunct to chemotherapy. There are a couple posters at AACR on it:
ETB receptor agonist, IRL-1620, enhances the efficacy of cyclophosphamide and cisplatin in ovarian tumor bearing mice. Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
and
IRL-1620 increases the efficacy of radiation treatment in mice bearing lymphoma cell induced tumors Monday, Apr 16, 2007, 1:00 PM - 5:00 PM
